Molecular Diagnostics Cancer Oncology - Global Market Size, Strategy and Forecasts - 2019 to 202

Attention: There is an updated edition available for this report.

Molecular Diagnostics Cancer Oncology - Global Market Size, Strategy and Forecasts - 2019 to 2023

A market that just keeps on growing. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge. Learn all about it in this new report from Howe Sound Research. A range of dynamic trends are pushing market growth and company valuations. Trends like ......

  • personalized medicine
  • pharmacogenomics
  • liquid biopsy
  • emergence of new economies with large markets
  • greater understanding of the role of genetic material in Disease and Health
Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the

In addition customization work, breakouts for particular segments, assistance and support is included free of charge with every report.

"Molecular Diagnostics Cancer Oncology - Global Market Size, Strategy and Forecasts - 2019 to 2023" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2018 United States Medicare Fee Payment Schedules to help understand test pricing in detail. See lists of all current FDA Approved Molecular Diagnostic Tests. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

1. Introduction and Market Definition
1.1 What is Molecular Diagnostics
1.2 The Diagnostics Revolution
1.3 Market Definition
1.3.1 Revenue Market Size
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 U.S. Medical Market and laboratory Testing - Perspective
1.5.1 U.S. Medicare Expenditures for Laboratory Testing
2. Market Overview
2.1 Market Participants
2.2 Market Segments
2.2.1 Traditional Market Segmentation
2.2.2 Laboratory Focus and Segmentation
2.3 Industry Structure
2.3.1 Hospital Testing Share
2.3.2 Economies of Scale
2.3.3 Physician Office Lab’s
2.3.4 Physician’s and POCT
2.4 Profiles of Key MDx Companies
10X Genomics
Abbott Laboratories
Adaptive Biotechnologies
Aethlon Medical
Agena Bioscience
Angle plc
ARUP Laboratories
Beckman Coulter
Becton Dickinson
Bioarray Genetics
Biodesix Inc.
Bristol-Myers Squibb
Cancer Genetics
Caris Molecular Diagnostics
CellMax Life
Charles River
Chronix Biomedical
Clearbridge BioMedics
Clinical Genomics
Cytolumina Technologies Corp.
Dako (Agilent)
Diagnologix LLC
Epic Sciences
Exosome Diagnostics
Fluidigm Corp
Fluxion Biosciences
Foundation Medicine
Genomic Health
Guardant Health
Horizon Discovery
HTG Molecular Diagnostics
Incell Dx
Integrated Diagnostics
Leica Biosystems
MDx Health
Merck & Co., Inc
Molecular Diagnostics for Cancer 2019 to 2023 Page | 7
Molecular MD
MRM Proteomics Inc
Myriad Genetics/Myriad RBM
New Oncology
Ortho Clinical Diagnostics
Perkin Elmer
Personal Genome Diagnostics
Protagen Diagnostics
Rarecells SAS
Roche Diagnostics
Silicon Biosystems
SRI International
Thermo Fisher
Vortex Biosciences
3. Market Trends
3.1 Factors Driving Growth
3.1.1 New Diagnostics Create New Markets
3.1.2 New Roles for Diagnostics.
3.1.3 Longevity and Outcomes
3.1.3 Expanding the Pharmaceutical Toolbox.
3.1.4 Regulatory Retreat
3.2 Factors Limiting Growth
3.2.1 Falling Prices
3.2.2 Lower Costs.
3.2.3 Testing as a Controllable Cost.
3.2.4 Wellness has a Downside
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role.
3.4 Diagnostic Technology Development
3.4.1 Next Generation Sequencing.
3.4.2 Shifting Role of Diagnostics
3.4.3 Multiplexing and Foundation One
3.4.4 Pharmacogenomics Technology
3.4.5 Whole Genome Sequencing
3.4.6 Gene Editing and Gene Therapy
4. Molecular Diagnostics Recent Developments
Recent Developments – Importance and How to Use This Section
Importance of These Developments
How to Use This Section
Icon Acquires MolecularMD
Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca
Adaptive Biotechnologies to Leverage Genentech, Microsoft Deals to Advance Immune Profiling Business 144
Illumina to Launch New NovaSeq Chip, iSeq Kit; Grow Oncology and Reproductive Health Business
UgenTec, MDxHealth Partner To Develop AI Software for Prostate Cancer Tests
Guardant Health, Core Diagnostics to Offer Liquid Biopsy in India
Invitae Q3 Revenues More Than Double
Illumina to Acquire Pacific Biosciences
Lung Cancer Panel From PlexBio Receives CE Mark
Thermo Fisher Scientific Gets CE-IVD Mark for Oncomine Dx
Merck KGaA, ArcherDx Partner to Develop CDx for Downstream Therapeutic
Foundation Medicine and Merck to Develop Diagnostic Tests for Keytruda
Cancer Genetics and NovellusDx to Merge
ApoCell Expands Immuno-Oncology Biomarker Services
MRM Proteomics Inc and Exactis Innovation Partner
Agilent Companion Diagnostic Gains FDA Approval in Urothelial Carcinoma
Fluidigm Partners with GenomOncology to Provide Immuno-Oncology Solution
MolecularMD Launches Validated Tumor Mutation Burden Assay
Minomic Secures Key Patent in the United States and China
Biocartis and Wondfo Announce Joint Venture
Five Prime Therapeutics Announces Collaboration with Roche to Develop Companion Diagnostics
Biodesix Acquires Integrated Diagnostics
Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx
Bio-Techne to Acquire Exosome Dx for Up to $575M
GRAIL Announces Data on Detection of Early-Stage Lung Cancers
CellMax Life, IncellDx Partner to Develop Circulating Tumor Cell Tests
Quest to Offer Thermo Fisher's Oncomine Dx Target Test
Angle, Abbott Ink Deal for Use of FISH With Harvested CTCs
Foundation Medicine to Profile Samples for European Cancer Network
GRAIL Details Plans for Early Cancer Detection Trials, Products
Avalon GloboCare, Da An Gene Collaborate on Liquid Biopsy Diagnostics
OncoDNA Inks Russian Distribution Deal With Genext
Biocept Prices $15M Public Offering
5. The Global Market for MDx Cancer
5.1 MDx Cancer – Global Market Overview by Country
5.1.1 Table – Global Market by Country
5.1.2 Chart - Global Market by Country
6. Global MDx Cancer Markets – By Type of Cancer
6.1 Global Market by Cancer Type - Overview
6.1.1 Table – Global Market by Cancer Type
6.1.2 Chart – Global Market by Cancer Type – 2018/2023 Comparison
6.1.3 Chart – Global Market by Cancer Type – 2018
6.1.4 Chart – Global Market by Cancer Type –2023
6.1.4 Chart – Global Market by Cancer Type – Share by Year
6.2 MDx Breast Cancer
6.2.1 Table Breast Cancer Testing – by Country
6.2.2 Chart - Breast Cancer Testing Growth
6.3 MDx Colorectal Cancer
6.3.1 Table Colorectal Cancer Testing – by Country
6.3.2 Chart - Colorectal Cancer Testing Growth
6.4 MDx Cervical Cancer
6.4.1 Table Cervical Cancer Testing – by Country
6.4.2 Chart - Cervical Cancer Testing Growth
6.5 MDx Lung Cancer
6.5.1 Table Lung Cancer Testing – by Country
6.5.2 Chart - Lung Cancer Testing Growth
6.6 MDx Precancer
6.2.1 Table Precancer Testing – by Country
6.6.2 Chart - Precancer Testing Growth
6.7 MDx Prostate Cancer
6.7.1 Table Prostate Cancer Testing – by Country
6.7.2 Chart - Prostate Cancer Testing Growth
6.8 MDx Melanoma
6.8.1 Table Melanoma Testing – by Country
6.8.2 Chart - Melanoma Testing Growth
6.9 MDx Blood Cancer
6.9.1 Table Blood Cancer Testing – by Country
6.9.2 Chart - Blood Cancer Testing Growth
6.10 MDx Other Cancer
6.10.1 Table Other Cancer Testing – by Country
6.10.2 Chart - Other Cancer Testing Growth
7. Cancer Treatment and Trials
7.1 FDA Cancer Drug Approvals by Year
7.2 Clinical Trials Started 2010 to 2016
7.3 Prevalence of Cancer Treatments – 2015
I. United States Medicare System: January 2018 Clinical Laboratory Fees Schedule – National Limit and
II. FDA Approved Human Genetic Tests
III. FDA Approved Microbial Tests
III. FDA Approved Pharmacogenomics Tests
Table of Tables
Table 1 Lab Spending 2014 to 2024
Table 2 Market Players by Type
Table 3 Clinical Laboratory Departments and Segments
Table 4 Laboratory Management Focus – Different Approaches
Table 5 Key Segmentation Variables Going Forward
Table 6 Five Factors Driving Growth
Table 7 Four Factors Limiting Growth
Table 8 Key Diagnostic Laboratory Technology Trends
Table 9 Next Generation Sequencing Technologies – Speed and Cost
Table 10 - Global MDx Cancer Market by Region
Table 11 Global Market by Cancer Type
Table 12 MDx Breast Cancer by Country
Table 13 MDx Colorectal Cancer by Country
Table 14 Cervical Cancer Testing by Country
Table 15 Lung Cancer Testing by Country
Table 16 Precancer Testing by Country
Table 17 Prostate Cancer Testing by Country
Table 18 MDx Melanoma by Country
Table 19 MDx Blood Cancer by Country
Table 20 MDx Other Cancer Testing by Country
Table 21 2018 Clinical Lab Fee Schedule
Table of Figures
Figure 1 Clinical Lab Spending 2014 to 2024
Figure 2 Growth in Aging Population
Figure 3 Death Rates from Cancer - USA
Figure 4 Comparing MDx Diagnostic and Traditional Testing
Figure 5 2018 Global Market Density Chart
Figure 6 MDx Market by Cancer - 2018 vs. 2023
Figure 7 Cancer Market 2018
Figure 8 Cancer Market 2023
Figure 9 MDx Cancer Share by Year
Figure 10 Breast Cancer Testing Growth
Figure 11 Colorectal Cancer Testing Growth
Figure 12 Cervical Cancer Testing Growth
Figure 13 Lung Cancer Testing Growth
Figure 14 Precancer Testing Growth
Figure 15 Prostate Cancer Testing Growth
Figure 16 Melanoma Testing Growth
Figure 17 Blood Cancer Testing Growth
Figure 18 Other Cancer Testing Growth
Figure 19 FDA Cancer Drug Approvals by Year
Figure 20 Clinical Trials for Immunotherapy by Year
Figure 21 Pie Chart of Prevalence of Cancer Treatments

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook